

Protalix BioTherapeutics, Inc.  
Form 8-K  
January 08, 2015

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 8, 2015**

---

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

|                                     |                                 |                            |
|-------------------------------------|---------------------------------|----------------------------|
| <b>Florida</b>                      | <b>001-33357</b>                | <b>65-0643773</b>          |
| <b>(State or other jurisdiction</b> |                                 | <b>(IRS Employer</b>       |
| <b>of incorporation)</b>            | <b>(Commission File Number)</b> | <b>Identification No.)</b> |

**2 Snunit Street**

**20100**

**Science Park, POB 455  
Carmiel, Israel  
(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code +972-4-988-9488**

**(Former name or former address, if changed since last report.)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ..Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ..Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ..Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ..Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events**

On January 8, 2015, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing positive interim efficacy and safety data from the Company’s ongoing phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated January 8, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: January 8, 2015 By: /s/ Moshe Manor

Name: Moshe Manor

Title: President and Chief Executive Officer